Aromatase inhibitors and fracture prevention – do 2017 guidelines work in real world?

Authors:

Abstract
Objectives: Aromatase inhibitor induced bone loss (AIBL) is a recognised adverse event with resultant increase in fracture risk. We aimed to determine the real-world impact of the 2017 consensus guidelines on AIBL and it is effective in fracture prevention. Methods: Over a 7-year study period, 1001 women prescribed AI were split in two groups. First group were offered bone active treatment based on NOS 2009 guidelines whereas the second group followed the 2017 consensus guidelines. Results: 1001 women were included. First group: 361 women had a baseline DEXA with 143 (40%) women had a normal DEXA, 174 (48%) had osteopenia and 44 (12%) had osteoporosis. Of the women with osteopenia, 44 (25%) women were offered treatment and 22 (13%) women had a fracture. Second group: 640 women had a baseline DEXA with 216 (33%) women were normal, 322(50%) had osteopenia and 107 (17%) had osteoporosis. Of the women with osteopenia, 127 (39%) women were offered treatment and 8 (2.5%) women had a fracture. Conclusions: Our study provides real world evidence of the success of 2017 consensus statement in lowering fracture risk. A significant reduction in fractures pre (13%) and post guidelines change (2.5%) was demonstrated (absolute risk reduction of 10.5%) which has implications for healthcare systems worldwide as we have demonstrated this approach can reduce morbidity.

This publication has 15 references indexed in Scilit: